Bone density loss from Anastrozole partially reverses after treatment stops
(Queen Mary University of London) A study by researchers from Queen Mary University of London shows that bone loss known to be associated with the use of the breast cancer prevention drug Anastrozole partially reverses, particularly at the lumbar spine, after stopping treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 21, 2021 Category: Cancer & Oncology Source Type: news
Phase I/II Trial To Evaluate Dual HER2 Combination Therapy in HR+, HER2+ Breast Cancer
The multi-center trial is comprised of 2 phases, with phase I determining the maximum tolerated dose of palbociclib and phase II determining the clinical benefit rate of treatment with anastrozole, palbociclib, trastuzumab, and pertuzumab. (Source: CancerNetwork)
Source: CancerNetwork - April 29, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Anastrozole Extends Breast Cancer Protection Once Stopped Anastrozole Extends Breast Cancer Protection Once Stopped
A 5-year regimen of anastrozole protects women against new breast cancers for at least another 5 years they stop taking the drug.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 18, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
SABCS: Anastrozole Tied to Lasting Reduction in Breast Cancer Risk
Breast cancer risk significantly lower at median follow - up of 131 months; effect continued after treatment (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 17, 2019 Category: Cancer & Oncology Tags: Family Medicine, Gynecology, Internal Medicine, Oncology, Pharmacy, Conference News, Source Type: news
SABCS: Anastrozole Tied to Lasting Reduction in Breast Cancer Risk
TUESDAY, Dec. 17, 2019 -- Anastrozole is associated with a long-term reduction in breast cancer risk, even after treatment, according to a study published online Dec. 12 in The Lancet to coincide with the annual San Antonio Breast Cancer Symposium,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 17, 2019 Category: Pharmaceuticals Source Type: news
Drug that halves a woman's risk of breast cancer works for SEVEN YEARS after they stop taking it
Arimidex halves the risk of breast cancer in postmenopausal women. Now, a study at Queen Mary University of London shows these effects last for a further seven years. (Source: the Mail online | Health)
Source: the Mail online | Health - December 13, 2019 Category: Consumer Health News Source Type: news
Drug that prevents half of breast cancers carries on working
Anastrozole is available already, but doctors say substantially more women should be taking it. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - December 12, 2019 Category: Consumer Health News Source Type: news
Anastrozole Shows Long-Lasting Breast Cancer Prevention Power
THURSDAY, Dec. 12, 2019 -- Nearly six years after stopping a five-year regimen of the breast cancer drug anastrozole, women at high risk for breast cancer were 50% less likely to have been struck by the disease, new research shows.
The trial... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 12, 2019 Category: General Medicine Source Type: news
Long-Term Follow-Up Supports Anastrozole Treatment to Prevent Breast Cancer Recurrence
Five years of treatment with anastrozole safely and effectively prevented breast cancer recurrence in high-risk postmenopausal women at 10.9 years of follow-up. (Source: CancerNetwork)
Source: CancerNetwork - December 12, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news
IBIS-II study finds anastrozole reduces breast cancer rates for high risk postmenopausal women
(Queen Mary University of London) The Queen Mary University of London professor leading an international breast cancer study says anastrozole -- rather than tamoxifen -- should be the preventive drug-of-choice for post-menopausal women at increased risk of developing the disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 12, 2019 Category: Cancer & Oncology Source Type: news
Riskreducing medications for primary breast cancer: a network metaanalysis
This Cochrane Review of 6 studies (n=50,927 on 1 cancer prevention agent (CPA:tamoxifen/raloxifene/exemestane/anastrozole] or placebo) found for women at above ‐average risk of developing breast cancer, CPAs can reduce incidence of this disease. Aromatase inhibitors appear to be more effective. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 29, 2019 Category: Consumer Health News Source Type: news
Fulvestrant-anastrozole Combo Improves Survival in Metastatic Breast Cancer Fulvestrant-anastrozole Combo Improves Survival in Metastatic Breast Cancer
More than six years after a study showed that women with hormone-receptor-positive metastatic breast cancer benefit from a combination of anastrozole and fulvestrant, extended results show the trend has become even more pronounced, but mostly for women not previously exposed to tamoxifen.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 28, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Fulvestrant plus anastrozole extends lives of women with advanced HR+ breast cancer
(SWOG) Women with metastatic hormone receptor-positive breast cancer live longer when they receive a combination of two anti-estrogen drugs, fulvestrant and anastrozole, compared with treatment with anastrozole alone, according to results of a SWOG Cancer Research Network study appearing in the New England Journal of Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 27, 2019 Category: Cancer & Oncology Source Type: news
Zoledronic acid improves disease-free survival in premenopausal HR+ early breast cancer
(European Society for Medical Oncology) Adjuvant treatment with the bone sparing drug zoledronic acid plus hormonal therapy with the aromatase inhibitor letrozole significantly increases disease-free survival compared to tamoxifen in premenopausal women with hormone receptor positive (HR+) early breast cancer, according to results reported at ESMO 2018 Congress in Munich. It is the first study to assess this specific combination in premenopausal breast cancer and adds to previous observations with zoledronic acid and anastrozole in premenopausal women receiving ovarian suppression. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 22, 2018 Category: Cancer & Oncology Source Type: news
Drug combination effective to treat male infertility
Combination therapy of drugs clomiphene citrate and anastrozole is a safe and effective way to treat infertility in males, a study inBJU International suggests.News Medical (Source: Society for Endocrinology)
Source: Society for Endocrinology - June 6, 2018 Category: Endocrinology Source Type: news
